Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

LLMC 2020 | New therapeutic options for low-risk MDS

Sangmin Lee • 21 Oct 2020
LLMC 2020
Myelodysplastic Syndromes Decitabine Luspatercept
ASCERTAIN MEDALIST

Sangmin Lee, MD, Weill Cornell Medical College, New York City, NY, outlines discusses recently approved treatments for low-risk myelodysplastic syndromes (MDS). He discusses the approval of luspatercept for low-risk MDS patients with the SF3B1 mutation as a result of the Phase III MEDALIST clinical trial (NCT02631070), and the approval of an oral form of the hypomethylating agent decitabine as a result of the Phase III ASCERTAIN trial (NCT03306264). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Disclosures

Consultancy: AstraZeneca, BMS, Jazz, Roche Diagnostics
DSMB membership: Helsinn

More from Sangmin Lee

1:45
Updates on the treatment of MDS
Sangmin Lee • 20 Oct 2021
1:07
Challenges in treating AML
Sangmin Lee • 20 Oct 2021
1:13
Rare blood diseases at LLM 2021
Sangmin Lee • 20 Oct 2021
2:10
Updated overall survival data on eltanexor for HMA-refractory MDS
Sangmin Lee • 4 Jun 2021

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:19
Key clinical trials in MDS taking place in the US
Guillermo Garcia-Manero • 9 Apr 2024
1:34
Sequencing of agents in LR-MDS
Guillermo Garcia-Manero • 9 Apr 2024
1:21
HMAs for MDS- a party of one
Guillermo Garcia-Manero • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals